SCHEMBL3700293

SCHEMBL3700293

CCOC(=O)c1cc(Sc2ccc(Cl)nc2)n(-c2ccc(C)cc2F)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TP53 P04637 2/20 0.38
JMJD6 Q6NYC1 1/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
CA9 Q16790 1/20 0.35
THRB P10828 1/20 0.35
LMNA P02545 1/20 0.35
SLC34A1 Q06495 1/20 0.34
KMT2A Q03164 1/20 0.34
CHRNA7 P36544 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3697504 0.93 MAPT (0.39) MAPTGAAKDM4ENPSR1ATM
SCHEMBL3704506 0.93 KDM4E (0.40) MAPTGAAKDM4ENPSR1ATM
SCHEMBL3694787 0.90 NPSR1 (0.45) MAPTGAANPSR1TP53RAB9A
SCHEMBL3692782 0.87 THRB (0.38) MAPTGAAKDM4ENPSR1ATM
SCHEMBL3706032 0.86 TP53 (0.41) MAPTGAAKDM4ENPSR1TP53
SCHEMBL3696333 0.86 TP53 (0.41) MAPTGAANPSR1TP53JMJD6
SCHEMBL3700030 0.86 TP53 (0.41) MAPTGAANPSR1TP53JMJD6
SCHEMBL3712644 0.85 THRB (0.38) MAPTGAAKDM4ENPSR1ATM
SCHEMBL3702451 0.85 THRB (0.38) MAPTGAAKDM4ENPSR1ATM
SCHEMBL3694337 0.85 MALT1 (0.35) RAB9ANPC1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
EP-2190822-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-06-02 EP disclosed
WO-2009041705-A9 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2009-08-13 WO disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2009041705-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 MAPT 4258/4885GAA 7/4885KDM4E 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.